{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:15Z","timestamp":1792067655578,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Ovid MEDLINE, SCOPUS, and Cochrane Database of Systematic Reviews were searched up to September 2019. Out of 699 studies, we included 16 studies describing the treatment outcomes of rituximab in adult patients with FSGS or MCD. Results were reported in remission rate and relapse rate. Serious adverse events were also reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 16 studies were included in our review and analysis. All studies were observational studies and included a total of 221 patients (23.1% FSGS, 76.9% MCD). Mean follow-up duration was 26.3\u2009\u00b1\u200912.8\u2009months. From the analysis of five studies with FSGS patients (<jats:italic>n<\/jats:italic>\u2009=\u200951), the overall remission rate and relapse rate of RTX therapy was 53.6% (95% CI, 15.8\u201387.6%) and 47.3% (95% CI, 25.4\u201370.2%), respectively. Complete remission occurred in 42.9%. In contrast, from the analysis of 11 studies with MCD patients (<jats:italic>n<\/jats:italic>\u2009=\u2009170), the overall remission rate and relapse rate of RTX therapy was 80.3% (95% CI, 68.5\u201388.5%) and 35.9% (95% CI, 25.1\u201348.4), respectively. Complete remission occurred in 74.7%. Subgroup analyses showed that overall remission and relapse were not different after adjusted for study year and RTX dose for both FSGS and MCD. Incidence of serious adverse events was 0.092 events\/year.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Rituximab may be considered as an additional treatment to the standard therapy for adult patients with FSGS and MCD. Remissions and relapses are similar between FSGS and MCD. Serious adverse effects of rituximab were uncommon. We encourage further randomized controlled trials to confirm the efficacy of rituximab therapy in these patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01797-7","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:02:41Z","timestamp":1586959361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Panupong","family":"Hansrivijit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrollah","family":"Ghahramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"6","key":"1797_CR1","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/ki.1986.130","volume":"29","author":"F Nolasco","year":"1986","unstructured":"Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986;29(6):1215\u201323.","journal-title":"Kidney Int"},{"issue":"3","key":"1797_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1797_CR3","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","volume":"15","author":"MJ Chun","year":"2004","unstructured":"Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1797_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1681\/ASN.2004070593","volume":"16","author":"S Troyanov","year":"2005","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1797_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2013;28(2):257\u201364.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"5","key":"1797_CR6","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910\u20135.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1797_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytula","year":"2010","unstructured":"Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2010;25(3):461\u20138.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"4","key":"1797_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000360908","volume":"39","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol. 2014;39(4):322\u201330.","journal-title":"Am J Nephrol"},{"issue":"7","key":"1797_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"1797_CR10","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I et al: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. (1756\u20131833 (Electronic))."},{"key":"1797_CR11","unstructured":"U.S. Food and Drug Administration. WHat is a Serious Adverse Event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed on 29 Feb 2020."},{"issue":"8746","key":"1797_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867\u201372.","journal-title":"Lancet"},{"issue":"7414","key":"1797_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"8","key":"1797_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2215\/CJN.00570109","volume":"4","author":"G Fernandez-Fresnedo","year":"2009","unstructured":"Fernandez-Fresnedo G, Segarra A, Gonz\u00e1lez E, Alexandru S, Delgado R, Ramos N, Egido JS, Praga M. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1797_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5414\/CN107092","volume":"76","author":"E Hoxha","year":"2011","unstructured":"Hoxha E, Stahl RAK, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol. 2011;76(2):151\u20138.","journal-title":"Clin Nephrol"},{"issue":"2","key":"1797_CR16","doi-asserted-by":"publisher","first-page":"c98","DOI":"10.1159\/000319656","volume":"117","author":"H Sugiura","year":"2011","unstructured":"Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98\u2013c105.","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"1797_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11255-012-0206-0","volume":"45","author":"WY Kong","year":"2013","unstructured":"Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol. 2013;45(3):795\u2013802.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1797_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Desch\u00eanes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):511\u20136.","journal-title":"Kidney Int"},{"issue":"5","key":"1797_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28(5):1225\u201332.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1797_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ndt\/gft312","volume":"29","author":"A Bruchfeld","year":"2014","unstructured":"Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2014;29(4):851\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1797_CR21","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","volume":"29","author":"J Guitard","year":"2014","unstructured":"Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducret F, Presne C, Pirson Y, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29(11):2084\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1797_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25(4):850\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1797_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/nep.12744","volume":"21","author":"E Papakrivopoulou","year":"2016","unstructured":"Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology. 2016;21(10):893\u2013900.","journal-title":"Nephrology"},{"issue":"1","key":"1797_CR24","first-page":"16","volume":"10","author":"C King","year":"2017","unstructured":"King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J. 2017;10(1):16\u20139.","journal-title":"Clin Kidney J"},{"issue":"55","key":"1797_CR25","doi-asserted-by":"publisher","first-page":"93438","DOI":"10.18632\/oncotarget.21833","volume":"8","author":"H Ren","year":"2017","unstructured":"Ren H, Lin L, Shen P, Li X, Xie J, Pan X, Zhang W, Chen N. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis. Oncotarget. 2017;8(55):93438\u201343.","journal-title":"Oncotarget"},{"issue":"2","key":"1797_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000477944","volume":"46","author":"D Roccatello","year":"2017","unstructured":"Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Barreca A, Fenoglio R, Baldovino S, Menegatti E. High-dose rituximab ineffective for focal segmental Glomerulosclerosis: a long-term observation study. Am J Nephrol. 2017;46(2):108\u201313.","journal-title":"Am J Nephrol"},{"issue":"2","key":"1797_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/ckj\/sfy067","volume":"12","author":"FB Cortazar","year":"2018","unstructured":"Cortazar FB, Rosenthal J, Laliberte K, Niles JL. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome. Clin Kidney J. 2018;12(2):224\u201331.","journal-title":"Clin Kidney J"},{"issue":"48","key":"1797_CR28","doi-asserted-by":"publisher","first-page":"28799","DOI":"10.18632\/oncotarget.25612","volume":"9","author":"R Fenoglio","year":"2018","unstructured":"Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, Menegatti E, Roccatello D. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018;9(48):28799\u2013804.","journal-title":"Oncotarget"},{"key":"1797_CR29","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology. 2019;24(12):1241\u201347.","DOI":"10.1111\/nep.13554"},{"issue":"3","key":"1797_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ndt\/14.3.713","volume":"14","author":"JG de Oliveira","year":"1999","unstructured":"de Oliveira JG, Xavier P, Carvalho E, Ramos JP, Magalhaes MC, Mendes AA, Faria V, Guerra LE. T lymphocyte subsets and cytokine production by graft-infiltrating cells in FSGS recurrence post-transplantation. Nephrol Dial Transplant. 1999;14(3):713\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1797_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","volume":"104","author":"C Bezombes","year":"2004","unstructured":"Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S, Jaffrezou JP, Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104(4):1166\u201373.","journal-title":"Blood"},{"issue":"3","key":"1797_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.bbamcr.2005.09.001","volume":"1746","author":"CR Bollinger","year":"2005","unstructured":"Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta. 2005;1746(3):284\u201394.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1797_CR33","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","volume":"107","author":"F Perosa","year":"2006","unstructured":"Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107(3):1070\u20137.","journal-title":"Blood"},{"issue":"85","key":"1797_CR34","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.","journal-title":"Sci Transl Med"},{"issue":"7\u20138","key":"1797_CR35","first-page":"626","volume":"61","author":"M Simkovic","year":"2015","unstructured":"Simkovic M, Vodarek P, Motyckova M, Zak P, Smolej L. Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia. Vnitr Lek. 2015;61(7\u20138):626\u201332.","journal-title":"Vnitr Lek"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01797-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:56:25Z","timestamp":1618444585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01797-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01797-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Charat Thongprayoon, MD is a member of the editorial board for BMC Nephrology journal. Other authors declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}